Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ASP3082 | 首个进入临床阶段的 KRAS G12D 降解剂（CAS No.: 2821793-99-9） - Book学术
ASP3082 (Setidegrasib) | KRAS G12D PROTAC Degrader | Selleck Chemicals
ASP3082 | KRAS G12D PROTAC | Probechem Biochemicals
Raffaele Colombo: Efficacy and Safety of ASP3082 in NSCLC at Targets25 ...
ASP3082 in Patients With Solid Tumors and KRAS G12D Mutations - YouTube
Discovery of KRAS(G12D) selective degrader ASP3082 | Communications ...
ASP3082 for Tumors, Solid Clinical Trial 2022 | Power
ASP3082 for Solid Tumors Clinical Trial 2023 | Power
ASP3082 for Cancer Clinical Trial 2025 | Power
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo ...
【ASP3082】進行性固形がん / 第I相試験 / ASP3082 / KRAS G12D阻害剤 / EGFR阻害剤 | 国立がん研究 ...
Phase I trial of ASP3082 in KRAS G12D-positive solid tumors - VJOncology
A Phase 1 Study of ASP3082 in Participants With Previously Treated ...
ASP3082 mostra atividade antitumoral promissora e perfil de segurança ...
Multiple Strategies to Develop Small Molecular KRAS Directly Bound ...
KRAS Cancer ConnectsESMO24 abstract608O - Preliminary safety and ...
ESMO 2024 – Astellas defends its degrader | ApexOnco - Clinical Trials ...
医药魔方 | 降解剂“竞技”AACR - 知乎
全球首个！安斯泰来KRAS G12D降解剂在华申报临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
New Molecular Targets, Technologies, and Cancer Treatments | Blog | AACR
RAS degraders: The new frontier for RAS-driven cancers: Molecular Therapy
双癌种新突破！2026 ASCO GI 揭秘，佐妥昔单抗联合疗法一线治疗 G/GEJ 癌新突破， ASP3082降解剂治疗胰腺癌最新临床数据 ...
Novel cancer-drug strategy could hit notorious proteins
Setidegrasib (ASP-3082) | KRAS G12D PROTAC Degrader | MedChemExpress
Frontiers | KRAS G12D targeted therapies for pancreatic cancer: Has the ...
三款 「first-in-class」PROTAC ，首次公布临床结果
MRTX1133和ASP3082（西妥昔单抗）KRAS G12D基因突变实体肿瘤新药-美联医邦
608O Preliminary safety and clinical activity of ASP3082, a first-in ...
Abstract A070: Optimal efficacious dose prediction of a novel protein ...
Phase 1 evaluation of ASP3082, a first-in-class selective protein ...
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and ...
Astellas at JPM: Science to change tomorrow
RCSB PDB - 9L6F: Crystal structure of KRas G12D (GDP) in complex with ...
KRAS G12D inhibitor 7 | KRAS G12D 阻害剤 | MedChemExpress
ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable ...
(ASP 3082)-药物靶点：KRAS G12D_在研适应症：实体瘤_专利_临床_研发
TPD: turning undruggable targets into druggable targets
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs ...
Next batter up! Targeting cancers with KRAS-G12D mutations: Trends in ...
全球首个KRAS G12D蛋白降解药物ASP3082注射液在中国的临床试验申请获批,剑指多种实体瘤_全球肿瘤医生网
KRAS(G12D) Coupled Nucleotide Exchange Assay Kit | BPS Bioscience ...
速递｜2024 年最新 KRAS 临床药物进展 - 知乎
Targeting cancer with small-molecule pan-KRAS degraders | Science
KRAS G12D: The Next Frontier in Cancer Therapy | MedChemExpress
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V ...
化合物はそえるだけ - Azarashi_Pandaの日記
KRAS G12D inhibitor 17 | TargetMol
2023年，PROTACs进军肺癌的临床之年医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure ...
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis
Novel KRAS Mutation Degrader’s Safety, Antitumor Activity Positive in ...
KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting ...
Setidegrasib, 2821793-99-9 | BroadPharm
The KRAS crowd targets its next cancer mutations
Full article: A patent review of von Hippel-Lindau (VHL)-recruiting ...
Proposed mechanism for self-assembly of oncogenic KRAS G12D into dimers ...
KRAS G12D変異陽性で既治療の進行固形癌にKRAS G12D分解誘導薬ASP3082は有望【ESMO 2024】：がんナビ
アステラス製薬、蛋白質分解誘導薬ASP3082の第1相結果は2023年度に判明：日経バイオテクONLINE
ASP-3082, a PROTAC that selectively degrades KRAS G12D protein, shows ...
ESMO24 Oncology Report – OBiS
国内首款KRAS G12D蛋白降解剂新药ASP3082获批IND！
KRAS G12D抑制剂：GFH375、MRTX1133、HRS-4642、NT-112、ASP3082临床研究进展！ - 知乎
